The Glut/Cre ratios in cortical regions from IID-positive glioma patients were significantly higher than those measured in healthy volunteers (0.28 ± 0.16 versus 0.12 ± 0.04, P = 0.0334, one-tailed t-test, Fig. 3E, IID-positive glioma patients: n = 6, healthy controls: n = 5). This evidence concerns the gene SLC2A1 and central nervous system cancer.